archive_header_en_20251203154432269.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts.<br>If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.<br>We will reply after confirming that you were a participant.<br>Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Experience of urgent drug development in a pandemic environment, delivering the first approved anti-COVID-19 treatment - Trials, Access, and Manufacturing -

 With no signs of COVID-19 converging, people are looking forward to developing effective treatments as soon as possible while seeking more effective infection prevention measures. In particular, correct infection prevention measures are extremely important for patients (underlying diseases such as cardiovascular disease) and elderly people with severe or high case fatality rates. Therefore, people’s expectations for the dissemination of right information on COVID-19 by pharmacists and pharmaceutical researchers and the development of new preventive measures and drugs are expected to be very high. The International Federation of Pharmaceutical Sciences (FIP) continues to provide useful information to people promptly as guidance for SARS-CoV-2 (https://www.fip.org/coronavirus). This symposium introduces efforts by pharmaceutical professionals from various stakeholders (international pharmacy federation, regulatory agency, pharmacist, and company) regarding the development and appropriate use of drugs for COVID-19, and shares information with participants. We will provide a place to discuss future activities of pharmaceutical professionals aiming at the COVID-19 pandemic end.

The Pharmaceutical Society of Japan

The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)

The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)

[IS01-4]Experience of urgent drug development in a pandemic environment, delivering the first approved anti-COVID-19 treatment - Trials, Access, and Manufacturing -

Password required to view